Clinical Pharmacology and Therapeutics

Evaluation of Potential Racial Disparities in CYP2C19-Guided P2Y12 Inhibitor Prescribing After Percutaneous Coronary Intervention.  113:615-623. 2023

Personalizing Direct Oral Anticoagulant Therapy for a Diverse Population: Role of Race, Kidney Function, Drug Interactions, and Pharmacogenetics.  113:585-599. 2023

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update.  112:959-967. 2022

ISPE-Endorsed Guidance in Using Electronic Health Records for Comparative Effectiveness Research in COVID-19: Opportunities and Trade-Offs.  112:990-999. 2022

Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles.  111:950-955. 2022

Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatment-Resistant Epilepsy.  110:1368-1380. 2021

Translational Pharmacogenomics: Discovery, Evidence Synthesis and Delivery of Race-Conscious Medicine.  110:909-925. 2021

Adverse Cardiovascular Outcomes and Antihypertensive Treatment: A Genome-Wide Interaction Meta-Analysis in the International Consortium for Antihypertensive Pharmacogenomics Studies.  110:723-732. 2021

Opportunity for Genotype-Guided Prescribing Among Adult Patients in 11 US Health Systems.  110:179-188. 2021

Toward Consensus on Correct Interpretation of Protein Binding in Plasma and Other Biological Matrices for COVID-19 Therapeutic Development.  110:64-68. 2021

Effects of NT5C2 Germline Variants on 6-Mecaptopurine Metabolism in Children With Acute Lymphoblastic Leukemia.  109:1538-1545. 2021

Thromboembolic and Hemorrhagic Outcomes in the Direct Oral Anticoagulant Trials Across the Spectrum of Kidney Function.  109:1593-1605. 2021

Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.  109:705-715. 2021

Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants.  109:253-262. 2021

Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.  107:1420-1433. 2020

Pharmacodynamics of Glyburide, Metformin, and Glyburide/Metformin Combination Therapy in the Treatment of Gestational Diabetes Mellitus.  107:1362-1372. 2020

Innovations in Targeted Anti-Adhesion Treatment for Sickle Cell Disease.  107:140-146. 2020

Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.  105:1477-1491. 2019

Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.  104:664-674. 2018

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.  102:397-404. 2017

Precision Medicine at the University of Alabama at Birmingham: Laying the Foundational Processes Through Implementation of Genotype-Guided Antiplatelet Therapy.  102:493-501. 2017

Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait.  101:373-381. 2017

Pharmacokinetics, pharmacodynamics, and safety of lisinopril in pediatric kidney transplant patients: Implications for starting dose selection.  98:25-33. 2015

Helicase-primase as a target of new therapies for herpes simplex virus infections.  97:66-78. 2015

The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.  96:380-389. 2014

Network medicine: Finding the links to personalized therapy.  94:613-616. 2013

Erratum: Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects (Clinical Pharmacology and Therapeutics (1995) 58 (44-53) DOI: 10.1016/0009-9236(95)90071-3).  89:320. 2011

Determination of appropriate dosing of influenza drugs in pediatric patients.  88:704-707. 2010

Treatment of herpes simplex virus infections in pediatric patients: Current status and future needs.  88:720-724. 2010

Integration of genetic, clinical, and INR data to refine warfarin dosing.  87:572-578. 2010

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.  83:312-321. 2008

Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients.  83:281-287. 2008

New pre-pandemic influenza vaccines: An egg- and adjuvant-independent human adenoviral vector strategy induces long-lasting protective immune responses in mice.  82:665-671. 2007

Ganciclovir population pharmacokinetics in neonates following intravenous administration of ganciclovir and oral administration of a liquid valganciclovir formulation.  81:867-872. 2007

The role of public policy in treating the epidemic of global obesity.  81:772-775. 2007

Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysis.  72:546-555. 2002

Pharmacokinetic strategies for concentration-targeted therapy with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV).  65:161. 1999

Concentration-controlled zidovudine therapy.  64:331-338. 1998

Comparative sexual side effects of bupropion, fluoxetine, paroxetine, and sertraline.  61:476-487. 1997

Pharmacokinetics of an anti-human immunodeficiency virus antisense oligodeoxynucleotide phosphorothioate (GEM 91) in HIV-infected subjects.  58:44-53. 1995

Linear single‐dose pharmacokinetics of ganciclovir in newborns with congenital cytomegalovirus infections.  53:15-21. 1993

Pharmacokinetics of esmolol and ASL-8123 in renal failure.  45:321-327. 1989

Rapid development of enhanced clearance after high-dose cyclophosphamide.  44:622-628. 1988

Enalapril in low-renin essential hypertension.  34:297-302. 1983

Lofexidine and clonidine in moderate essential hypertension.  30:752-757. 1981

Plasma levels and urinary excretion of vidarabine after repeated dosing.  27:690-696. 1980

Acyclovir kinetics after intravenous infusion.  26:718-728. 1979